Drug intelligence / Profile preview

INT-101

Development stage: Preclinical
Lead developer: Integrated Nanotherapeutics
Modality: Small Molecules, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

**INT-101** is Integrated Nanotherapeutics' preclinical, antigen-specific immune-tolerizing therapeutic for type 1 diabetes. It is a multi-cargo lipid-nanoparticle product that co-delivers mRNA encoding pancreatic beta-cell antigens with small-molecule immunomodulators in the same nanoparticle. The approach is intended to restore immune tolerance to beta cells, suppress the pathogenic autoimmune response, preserve endogenous insulin-producing cells, and avoid chronic systemic immunosuppression. ([integratedntx.com](https://integratedntx.com/app))

Other names: INT tolerizing LNP

Beyond the preview

Go deeper on INT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-101.

Explore the full profile